Skip to main content

Table 3 Characteristics and management of study participants with type 2 diabetes mellitus

From: Evaluating the Diabetes–Cardiology interface: a glimpse into the diabetes management of cardiology inpatients in western Sydney’s ‘diabetes hotspot’ and the establishment of a novel model of care

Parameter N = 99
Incident T2D 14 (14%)
 Referred for inpatient diabetes review 0/14
 New diagnosis mentioned in discharge letter 3/14 (21%)
 New diagnosis coded for in medical record 5/14 (36%)
 Recommended for endocrinology review after discharge 0/14
Known T2D 85 (85%)
 Referred for inpatient diabetes review 9/85 (11%)
 Diagnosis mentioned in discharge letter 82/85 (96%)
 Diagnosis coded for in medical record 82/85 (96%)
 Recommended for endocrinology review after discharge 11/85 (13%)
Management of known T2D 85 (85%)
 Hyperglycaemia 23/85 (27%)
 Hypoglycaemia 6/85 (7%)
 HbA1c > 7% (> 53 mmol/mol) 43/85 (56%)
Microvascular complications 40 (40%)
 Peripheral neuropathy 7 (7%)
 Retinopathy 5 (5%)
 Nephropathy (2 on dialysis) 46 (46%)
Macrovascular complications 63 (63%)
 Coronary artery disease 51 (51%)
 Ischaemic heart disease 53 (53%)
 Peripheral vascular disease 6 (6%)
 Carotid stenosis 4 (4%)
 Stroke/transient ischaemic attack 12 (12%)
Diabetes treatment
 Metformin 61 (62%)
 Sulphonylurea 29 (29%)
 Dipeptidyl peptidase-4 inhibitor 13 (13%)
 Sodium glucose co-transporter 2 inhibitor 2 (2%)
 Glucagon-like peptide-1 receptor analogue 0
 Acarbose 0
 Thiazolidinediones 0
 None 26 (26%)
 Insulin 17 (17%)
  Mean total daily dose (U) 77.7 ± 53
  Basal (mean HbA1c 78 mmol/mol, 9.3%) 4/17 (24%)
  Premixed (mean HbA1c 68 mmol/mol, 8.4%) 8/17 (47%)
  Basal-bolus (mean HbA1c 56 mmol/mol, 7.3%) 5/17 (29%)